Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211796 · ClinicalTrials.gov registry record · Phase 4
Divalproex Sodium ER in Adult Autism
A Phase 4 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT00211796 is a Phase 4 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 10 participants.
The verdict
NCT00211796, a Phase 4 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
12-week open label treatment trial of divalproex sodium extended release (Depakote ER) in 10 patients with a diagnosis of autism. Our objective is to determine how well these patients can tolerate the prescribed doses and what added benefits can be attributed to divalproex sodium ER.
Interventions
- DRUG Divalproex Sodium ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-04 |
| Est. Completion | 2007-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00211796
The ClinicalTrials.gov registry entry for NCT00211796 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Divalproex Sodium ER is the first listed.
NCT00211796 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00211796 about?
NCT00211796 is a clinical study titled "Divalproex Sodium ER in Adult Autism". 12-week open label treatment trial of divalproex sodium extended release (Depakote ER) in 10 patients with a diagnosis of autism. Our objective is to determine how well these patients can tolerate the prescribed doses and what added benefits can be attributed to divalproex sodium ER.
What is the current status of trial NCT00211796?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2005-04. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00211796?
The interventions under investigation include: Divalproex Sodium ER (DRUG).
Who is sponsoring clinical trial NCT00211796?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.